Table 3.
Induction immunosuppression and main post-operative complications
| 20-year survivors (n = 28) | Non-20-year survivors (n = 104) | p | |
|---|---|---|---|
| Induction immunosuppression | 0.61 | ||
| CyA-St | 22 (78 %) | 73 (72 %) | |
| Tac-St | 6 (22 %) | 19 (19 %) | |
| Cya-St-AZA | – | 7 (7 %) | |
| St-OKT3 | – | 2 (2 %) | |
| Ischemia reperfusion injury | 0.32 | ||
| Mild | 13 (47 %) | 67 (65 %) | |
| Moderate | 11 (39 %) | 25 (25 %) | |
| Severe | 3 (11 %) | 7 (7 %) | |
| PNF | 1 (4 %) | 3 (3 %) | |
| CMV infection | 6 (21 %) | 36 (34 %) | 0.15 |
| Acute rejection | 15 (54 %) | 66 (65 %) | 0.25 |
| Chronic rejection | 2 (7 %) | 23 (22 %) | 0.06 |
| Technical complications | |||
| Artery thrombosis | – | 5 (5 %) | 0.58 |
| Portal thrombosis | – | 3 (3 %) | 0.99 |
| Hepatic vein stenosis | – | 1 (1 %) | 0.99 |
| Biliary complications | 6 (21 %) | 26 (25 %) | 0.69 |
| Renal dysfunction at end of the 1st yeara | 14 (50 %) | 42 (67 %) | 0.21 |
| Liver dysfunction at end of the 1st yearb | 5 (18 %) | 30 (45 %) | 0.01 |
| Retransplant | 3 (11 %) | 16 (15 %) | 0.53 |
CyA cyclosporine, St steroids, Aza azathioprine, Tac tacrolimus, PNF primary non-function, CMV cytomegalovirus
aDefined as estimated glomerular filtration rate <60 mL/min/1.73 m2
bDefined as AST/ALT ≥100 IU/L and/or total bilirubin ≥1.5 mg/dL